Adjuvant Treatment for Resected Lung Cancer
Name of the Trial
Why This Trial Is Important
The addition of the monoclonal antibody bevacizumab (Avastin) to chemotherapy has helped extend the lives of some patients with inoperable advanced or metastatic non-small-cell lung cancer (NSCLC). Now doctors are interested in determining whether the addition of bevacizumab to adjuvant chemotherapy can help patients with early NSCLC live longer following surgery to remove their tumors.
Bevacizumab blocks the activity of a protein called vascular endothelial growth factor (VEGF), which promotes the growth of blood vessels (angiogenesis) to tumors. Angiogenesis is essential for tumors to get the oxygen and nutrients they need to grow bigger than a few millimeters.
"Bevacizumab in addition to chemotherapy is proven to help people with advanced lung cancer live longer," said Dr. Wakelee. "Because of the way this agent works, we're hopeful that giving it along with chemotherapy to patients with completely resected early-stage lung cancer will help block the development of advanced disease and possibly produce a cure for some of these patients."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.